ライフサイエンスコーパス: escalation

1 0 mg methyldopa (a single dose, without dose escalation).

2 s, but usually did not lead to antibiotic de-escalation.

3 ant HER2-mutant cancer cells by gradual dose escalation.

4 ccal infection would allow for antibiotic de-escalation.

5 kinetic, safety, and activity data from dose escalation.

6 eight per day for 6 months, followed by dose escalation.

7 inflammatory toxicities, leading to dose de-escalation.

8 ccal infection would allow for antibiotic de-escalation.

9 s needed to obtain favorable results with de-escalation.

10 s, but usually did not lead to antibiotic de-escalation.

11 bute to both poorly controlled pain and dose escalation.

12 ability to discontinue PPIs without symptom escalation.

13 d a positive PCR result had antimicrobial de-escalation.

14 gulatory capacity and exacerbate opioid dose escalation.

15 on strategies for treatment escalation or de-escalation.

16 he phase 1b portion of this open-label, dose-escalation (3+3+3 design) study examined the maximum tol

17 n [+/-SD] age, 4.6+/-1.0 years) or with dose escalation (93 children; mean age, 4.8+/-0.9 years); the

18 Dynamic immune activation and a two-step escalation/activation pattern were observed.

19 otential correlates of AAM escalation and de-escalation after CTO PCI.

20 ere was no difference in need for antibiotic escalation after initial discontinuation (7.6 vs 4.3%, p

21 ere was no difference in need for antibiotic escalation after initial discontinuation (7.6% vs 4.3%,

22 trial testing an aggressive course of RT de-escalation after surgery.

23 ised, double-blind, placebo-controlled, dose-escalation, age-descending, phase 1/2 trial in Dhaka, Ba

24 s during pregnancy show extreme evolutionary escalation (akin to elaborate mating displays).

25 This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigat

26 randomised study composed of a phase 1b dose escalation and a phase 2 dose expansion at 11 hospitals

27 ng may be a powerful stewardship tool for de-escalation and avoidance of empirical anti-MRSA therapy.

28 id a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study at the Royal

29 as a single-arm, open-label, phase 1b-2 dose-escalation and cohort expansion study done at 11 academi

30 Radiation dose-escalation and consolidation chemotherapy have been asso

31 he frequency and potential correlates of AAM escalation and de-escalation after CTO PCI.

32 se approaches may provide means for rational escalation and de-escalation treatment strategies in HER

33 astrointestinal stromal tumour from the dose-escalation and dose-expansion parts, all doses), treatme

34 This was an open-label, dose-escalation and dose-expansion phase 1 trial done at eigh

35 e did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in

36 nnovaTV 201 is a phase 1-2, open-label, dose-escalation and dose-expansion study done at 21 centres i

37 We did a phase 1 dose-escalation and dose-expansion study.

38 NAVIGATOR is a two-part, open-label, dose-escalation and dose-expansion, phase 1 study done at 17

39 zation of therapy as well as at treatment de-escalation and escalation based on tumour biology and ea

40 Critical care had higher rates of both de-escalation and escalation compared with wards.

41 yelodysplastic syndromes in the phase 1 dose-escalation and expansion portions of the trial.

42 CC-122-NHL-001 was a phase 1b dose escalation and expansion study at eight sites in France,

43 an open-label, multicentre, phase 1-2, dose escalation and expansion study done in the Netherlands,

44 ted a multicenter, open-label, phase I, dose escalation and expansion study of ivosidenib in patients

45 We did a phase 1 dose-escalation and expansion study of ivosidenib monotherapy

46 ine from a large, multicenter, phase 1b dose-escalation and expansion study.

47 ytic leukemia were treated on a phase 1 dose escalation and expansion trial (NCT03019055) to evaluate

48 Here, in a phase Ib, dose escalation and expansion, trial for patients with advanc

49 esult correlated with unnecessary antibiotic escalation and exposure to broader-spectrum antibiotics

50 f mavorixafor from a phase 2 open-label dose-escalation and extension study in 8 adult patients with

51 s study were to investigate predictors of de-escalation and its impact on the outcome of patients wit

52 ed an electronic definition of antibiotic de-escalation and performed a retrospective study among fiv

53 The De-Escalation and Stopping Treatment with Imatinib, Nilotin

54 sociations of UAT results with antibiotic de-escalation, and associations of de-escalation with outco

55 sociations of UAT results with antibiotic de-escalation, and associations of de-escalation with outco

56 alization, functional class, medical therapy escalation, and BNP [brain natriuretic peptide]).

57 e to appropriate antibiotic escalation or de-escalation, and secondary outcomes included time to oral

58 n antegrade wire escalation, retrograde wire escalation, antegrade dissection and reentry (ADR), and

59 A standard, objective definition of de-escalation applied to electronic data could be useful fo

60 r kilogram of body weight per day) with dose escalation (approximately 30 mg per kilogram per day).

61 quencies of UAT and subsequent antibiotic de-escalation are unknown.

62 derately effective and safe medications with escalation as needed, or to use higher efficacy medicati

63 ning maybe used as a stewardship tool for de-escalation as well as avoidance of anti-MRSA therapy.

64 gned to receive intravenous haloperidol dose escalation at 2 mg every 4 h, neuroleptic rotation with

65 py as well as at treatment de-escalation and escalation based on tumour biology and early therapy res

66 Initial de-escalation before discontinuation might improve the succ

67 nhancing inhibitory control over opioid dose escalation behaviors.

68 AD patients, including 50 patients with dose escalation by post hoc analysis of the phase III trial o

69 This phase 1, open-label, dose-escalation clinical trial was done at the National Insti

70 Because of dose-limiting toxicities, a de-escalation cohort (10 mg lenalidomide) was initiated, an

71 017, we enrolled 46 patients: 24 in the dose-escalation cohort (n=14 chronic lymphocytic leukaemia or

72 with solid tumours were included in the dose-escalation cohort and 29 patients with solid tumours or

73 The dose-escalation cohort comprised patients aged 18 years or ol

74 DLTs were observed in the subsequent dose-de-escalation cohort, establishing the MTD and recommended

75 In the dose-escalation cohort, patients treated with 12 mg/kg MP0250

76 In the dose-escalation cohort, patients were treated in cycles of 28

77 Three BIIB092 dose escalation cohorts (150 mg, 700 mg, or 2100 mg; eight pa

78 emotherapy were allocated to venetoclax dose-escalation cohorts (range, 50-600 mg).

79 The phase 1 dose-escalation cohorts for each histology escalated independ

80 Ten dose-escalation cohorts of patients with advanced or metastat

81 Patients were enrolled into one of five dose-escalation cohorts, with dose-escalation done in a 3 + 3

82 ve patients were enrolled across the 10 dose-escalation cohorts.

83 cteremia with electronic isolate-specific de-escalation comments and daytime antibiotic stewardship p

84 e had higher rates of both de-escalation and escalation compared with wards.

85 There is a fear that resistance escalation could jeopardize malaria control efforts.

86 his phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial include

87 use genotypic RDTs to inform therapeutic de-escalation decisions should be aware of the incidence-ba

88 etitors' resource holding potential (RHP) in escalation decisions.

89 Both trials followed a 3 + 3 dose-escalation design allowing for a dose expansion cohort o

90 A randomized, double-blind, dose-escalation design was employed.

91 h (triplet therapy group) using a 3 + 3 dose escalation design with expansion cohorts.

92 e of five dose-escalation cohorts, with dose-escalation done in a 3 + 3 design.

93 We conducted an age de-escalation, dose-escalation randomized controlled trial

94 The dose-escalation dosing strategy represents an alternative app

95 to analyze factors associated with early de-escalation (EDE) and Cox regression for the impact of ED

96 EV-101 is a phase I dose escalation/expansion study that enrolled patients with N

97 led that rats with high, but not low cocaine escalation failed to exploit previous reward learning an

98 rate of UAT was strongly correlated with de-escalation following a positive test.

99 se of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant r

100 An escalation from a low dose (5 x 109 viral particles) to

101 r treatment due to injection safety and dose escalation (Genexol-PM(R)) compared to Taxol(R).

102 ithin 30 min and remained low at 24 h in the escalation group (n=10, mean RASS score change between 0

103 ulation consisted of 54 patients in the dose-escalation group and 62 in the standard-dose group.

104 ious adverse event: six patients in the dose-escalation group and eight patients in the standard-dose

105 Children in the dose-escalation group had fewer sickle cell-related adverse e

106 ial closure, 86% of the children in the dose-escalation group had reached the primary-outcome thresho

107 3%, 95% CI 29-56) of 54 patients in the dose-escalation group initiated cycle 3 versus 16 (26%, 15-37

108 re fatigue (seven [13%] patients in the dose-escalation group vs 11 [18%] in the standard-dose group)

109 Baseline TPS of dose escalation groups, either after 2 weeks or after week 4,

110 In the dose escalation, groups of 5 patients in 4 cohorts received a

111 Phase 1b dose escalation had a three-plus-three design and established

112 Two patients in the once-every-3-weeks dose escalation had dose-limiting grade 3 transaminitis.

113 in sub-Saharan Africa, hydroxyurea with dose escalation had superior clinical efficacy to that of fix

114 trend in decreased time to escalation or de-escalation (hazard ratio, 1.22; 95% confidence interval

115 sms underlying experience-induced aggression escalation, however, are poorly understood.

116 for at least 2 months before an initial food escalation (IFE) with a mix of up to 6 allergens.

117 anel result, including discontinuation or de-escalation in 48.2% of patients, resulting in an average

118 ons, de-escalation occurred in 14,138 (36%), escalation in 5,129 (13%), and antibiotics were unchange

119 eated doses of the agonist prevented ethanol escalation in an intermittent access 2BC paradigm (IA-2B

120 nge, we evaluated RSV post-F antigen dose de-escalation in BALB/c mice in the presence of a Th1-biasi

121 eneous by country region, with rapid initial escalation in Brazil's north and northeast.

122 lability independently predicted the rate of escalation in cocaine-taking behaviors.

123 tor and an indication for adjuvant treatment escalation in patients with head and neck squamous cell

124 De-escalation in patients with monomicrobial bacteremia due

125 a significant opportunity for antibiotic de-escalation in patients.

126 thcare utilization, treatment, and treatment escalation in people of non-white ethnicity and of more-

127 are needed about the safety of antibiotic de-escalation in specific clinical situations as a strategy

128 Dose escalation in T3-T4 tumors did not increase local contro

129 nhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of sta

130 ten deterioration in glucose control despite escalation in treatment.

131 PLX5622 prevented escalations in voluntary alcohol intake and decreased an

132 blood eosinophil count requiring therapeutic escalation) in the previous 12 months, and had a screeni

133 Patient characteristics associated with escalation included lung disease, ongoing angina, and pe

134 breast cancer, particularly if treatment de-escalation is being considered for small or node negativ

135 A dose escalation is planned in a subsequent phase I/II study t

136 During dose escalation, ivosidenib was administered orally at 200-12

137 regression for the impact of EDE and late de-escalation (LDE) on 30-day all-cause mortality.

138 o UK clinical research facilities, in an age-escalation manner, into 18-55 years, 56-69 years, and 70

139 tion (median rate ratio, 1.11; P=0.36) or de-escalation (median rate ratio, 1.10; P=0.20) compared to

140 There was minimal variation in either escalation (median rate ratio, 1.11; P=0.36) or de-escal

141 Our electronic de-escalation metric demonstrated variation among hospitals

142 endothelial cell level at day 8, using a de-escalation model.

143 programs (ASPs) promote the principle of de-escalation: moving from broad to narrow spectrum agents

144 45 received the masked study interventions (escalation n=15, rotation n=16, combination n=14).

145 ost common serious toxicity was hypotension (escalation n=6 [40%], rotation n=5 [31%], combination n=

146 rade wire escalation (N=90), retrograde wire escalation (N=24), ADR (N=35), and retrograde dissection

147 ee patients were treated with antegrade wire escalation (N=90), retrograde wire escalation (N=24), AD

148 Twenty-one patients (escalation, n = 12; expansion, n = 9) with advanced chon

149 A propensity score (PS) for EDE vs no de-escalation (NDE) was calculated.

150 Among 39,226 eligible admissions, de-escalation occurred in 14,138 (36%), escalation in 5,129

151 7 h, respectively; P < 0.05), and antibiotic escalations occurred more quickly than did deescalations

152 At full escalation of 45Q, delivered CO(2) costs from this secto

153 Conclusions Escalation or de-escalation of AAMs was less common than continuation fol

154 rotonergic neurons selectively modulates the escalation of aggression.

155 rences in neural activity predict the future escalation of alcohol drinking from casual to compulsive

156 ment of the neuronal ensemble, decreases the escalation of alcohol drinking, and decreases the intens

157 or Gram-positive BSIs but led to unnecessary escalation of antibiotics for Gram-negative BSIs.

158 a paucity of data on the effect of early de-escalation of antimicrobial therapy on rates of Clostrid

159 De-escalation of antiplatelet therapy at the time of BARC 3

160 De-escalation of antiplatelet therapy at the time of BARC 3

161 nts with moderate to severe COVID-19 reduced escalation of care and improved clinical outcomes.

162 luated, with a primary composite endpoint of escalation of care from ward to intensive care unit (ICU

163 90 days, which should be used to trigger an escalation of care to prevent failure to rescue and even

164 sequently transferred to acute hospitals for escalation of care, were reviewed.

165 lunted efferocytic signatures and led to the escalation of cell death-associated transcriptional sign

166 low- and middle-income countries, where the escalation of climate-related risks may prevent the achi

167 Appropriate triage and escalation of clinical care are crucial for this patient

168 e exacerbated with chronic exposure and with escalation of cocaine intake.

169 tic reversal learning task predicted greater escalation of cocaine self-administration behavior and g

170 Background Singapore saw an escalation of coronavirus disease 2019 (COVID-19) cases

171 into complementary animal models, including escalation of drug intake, punished drug seeking and tak

172 ils by the macrophages was influenced by the escalation of hPMN autophagy, which is an important even

173 These results suggest reciprocal escalation of immune and neonatal brain injury in a subs

174 istant responding, food reward tolerance and escalation of intake through 24-h energy intake and fixe

175 sic period (800-950 CE) is interpreted as an escalation of military tactics that played a role in the

176 Escalation of nicotine intake in smokers, or tolerance,

177 sions of N/OFQ (1 mug per site) reversed the escalation of oxycodone self-administration in HA rats b

178 40% VE against heterologous CHMI, while dose escalation of PfSPZ using single dose priming was not si

179 Our findings are of great importance for de-escalation of surgical strategies.

180 ER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial topic.

181 e report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combina

182 t strongly resemble toxic shock syndrome, an escalation of the cytotoxic adaptive immune response tri

183 ed, and policy-informed, with emphasis on de-escalation of therapy.

184 .62-39.46) for PH-related hospitalization or escalation of therapy.

185 sibility of using IL-6 or CRP level to guide escalation of treatment in patients with COVID-19-relate

186 spital challenge and propose a framework for escalation of treatment in such cases using intravenous

187 The hypothesis that de-escalation of treatment intensity for patients with p16+

188 We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults

189 We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine,

190 f HES-related symptoms necessitating therapy escalation or >=2 courses of blinded rescue oral cortico

191 associated with a trend in decreased time to escalation or de-escalation (hazard ratio, 1.22; 95% con

192 Conclusions Escalation or de-escalation of AAMs was less common than

193 In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a con

194 y outcome was time to appropriate antibiotic escalation or de-escalation, and secondary outcomes incl

195 cancer, focusing on strategies for treatment escalation or de-escalation.

196 mours (regardless of HER2 expression in dose escalation or HER2 expression or mutation in dose expans

197 mours (regardless of HER2 expression in dose escalation or HER2 expression or mutation in dose expans

198 mide or oral placebo with the option of dose escalation or reduction.

199 There were no dose de-escalations or dose-limiting toxicities and nivolumab 3

200 During dose escalation, oral venetoclax was administered at 400, 800

201 PLA micelles, as Genexol-PM(R), permits dose escalation over Taxol(R), enhancing antitumor efficacy i

202 inib was administered once daily in the dose-escalation part (starting dose of 30 mg, with increasing

203 y was assessed in all patients from the dose-escalation part and all patients with PDGFRA D842V-mutan

204 The dose-escalation part of the study included patients with unre

205 The primary endpoints of the phase 1a dose-escalation part of the study were safety and tolerabilit

206 was the maximum tolerated dose from the dose-escalation part).

207 In the dose-escalation part, 24 patients received MP0250 as a 3-hour

208 mmended phase 2 dose, and safety in the dose-escalation part, and overall response and safety in the

209 toff), 46 patients were enrolled in the dose-escalation part, including 20 patients with a PDGFRA D84

210 In the dose-escalation part, no dose limiting toxicity was reported

211 During dose escalation, participants received venetoclax orally once

212 ntergroup attitudes associated with conflict escalation, particularly among those who value consisten

213 (starting dose 80 mg/day orally with weekly escalation, per 40 mg increment, to 160 mg/day regorafen

214 One further death occurred in the dose-escalation phase (1.5 mg/kg cohort) due to disease progr

215 23 FGFR mRNA-unselected patients in the dose-escalation phase and 103 patients with FGFR mRNA-overexp

216 tients were enrolled and treated in the dose-escalation phase and 146 patients were enrolled and trea

217 0(6) CAR-positive (CAR+) T cells in the dose-escalation phase and 150x10(6) to 450x10(6) CAR+ T cells

218 open-label study consisted of a 6 week dose-escalation phase and a long-term maintenance phase (clin

219 s across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); o

220 ized, double-blind, placebo-controlled, dose-escalation Phase I trial.

221 Methods: The initial dose escalation phase of this first-in-humans prospective stu

222 The primary endpoint of the dose-escalation phase was to assess safety and ascertain the

223 e events reported more than once in the dose-escalation phase were keratitis (n=3) and fatigue (n=2).

224 For the dose-escalation phase, eligible patients had histologically o

225 ended phase 2 dose, determined from the dose-escalation phase, in biomarker-selected patients.

226 In the dose-escalation phase, nine patients were treated: three rece

227 During the dose escalation phase, patients were enrolled sequentially in

228 In the dose-escalation phase, trastuzumab duocarmazine was given at

229 During the dose-escalation phase, we evaluated three intermittent oral s

230 were no dose-limiting toxicities in the dose-escalation phase.

231 st administered dose (2.4 mg/kg) in the dose-escalation phase.

232 eligible patients were enrolled to the dose-escalation phase.

233 drug combination as determined from the dose-escalation phase.

234 were enrolled, with 68 patients in the dose-escalation phase.

235 -tolerated dose were not reached in the dose escalation phase.

236 , placebo-controlled, observer-blinded, dose-escalation, phase 1 trial conducted in the United States

237 in humans, we conducted an open-label, dose-escalation, Phase I clinical trial in liver transplantat

238 (micronized formulation) in the phase 1 dose escalation portion, and at 800 to 1200 mg in the phase 1

239 ants were enrolled sequentially using a dose-escalation protocol to receive 0.67 mg, 2 mg, or 6 mg GL

240 cation was not possible because of different escalation protocols in the study groups.

241 We conducted an age de-escalation, dose-escalation randomized controlled trial in Siaya County,

242 Diagnoses with lower de-escalation rates included intra-abdominal (23%) and skin

243 Aggressive RT de-escalation resulted in locoregional tumor control rates

244 ct size were compared between antegrade wire escalation, retrograde wire escalation, antegrade dissec

245 During dose escalation, rogaratinib was administered orally twice da

246 acebo once weekly for 30 weeks, after a dose-escalation schedule of 4 weeks of 0.25 mg semaglutide or

247 Early MCS escalation stabilized patients rapidly, reducing number

248 ported here are results of the phase 1a dose-escalation stage of the trial.

249 Regorafenib dosing strategies were a dose-escalation strategy (starting dose 80 mg/day orally with

250 morphisms (SNPs) from virus passaged in dose escalation studies in a nonhuman primate kidney epitheli

251 ng placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368

252 In this phase 1, dose-escalation study (VRC 608), conducted at the US National

253 We did a phase 1, dose-escalation study at three research hospitals in the USA.

254 This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/

255 was a phase 1, open-label, single-arm, dose-escalation study of GLS-5300 done at the Walter Reed Arm

256 Here, we describe a phase 1b, dose-escalation study to assess the safety and preliminary ef

257 Patients were enrolled in a 3 + 3 dose escalation study to evaluate DSTP3086S (0.3 to 2.8 mg/kg

258 This dose-escalation study, guided by pharmacokinetic and pharmaco

259 In a phase 1 dose-escalation study, the clinical pharmacokinetics for PT29

260 7) cells, or 1.8-2.4 x 10(8) cells in a dose-escalation study.

261 d for the appropriate dose in a phase I dose-escalation study.

262 t not benefit all patients, and treatment de-escalation through omission of chemotherapy has shown pr

263 o low-dose VWG OIT or placebo, with biweekly escalation to 1445 mg of wheat protein (WP).

264 RT dose 68.0 Gy to the primary tumor or dose escalation to 73.1 Gy.

265 During phase 1a, TY014 dose escalation to a maximum of 20 mg per kilogram of body we

266 osteroids, with pre-established criteria for escalation to immunomodulators (ie, thiopurines) or anti

267 Primary composite outcome (escalation to intensive care unit, mechanical ventilatio

268 In new users, initiation of or escalation to more potent and high dose opioids may cont

269 strategy in managing PTLD in SBTx and prompt escalation to rituximab and CTL is recommended.

270 strategy in managing PTLD in SBTx and prompt escalation to rituximab and/or CTL is recommended.

271 ds remain undetermined, however, and whether escalation to the maximum tolerated dose confers clinica

272 heretofore unrealized opportunities for dose escalation to the tumor bed, capabilities that promise t

273 ong acting opioid prescriptions, or new dose escalations to > 100 mg OME).

274 provide means for rational escalation and de-escalation treatment strategies in HER2-positive breast

275 We conducted a first-in-human, phase 1 dose-escalation trial of autologous macrophage therapy in nin

276 s enrolled on dose level 1 in a phase 1 dose-escalation trial of autologous NKT cells engineered to c

277 A phase 1, placebo-controlled, dose-escalation trial was conducted in 230 healthy adults to

278 hase 1, randomised, placebo-controlled, dose-escalation trial was done at one clinical research centr

279 Considerations for the development of de-escalation trials for systemic adjuvant treatment, inclu

280 To address this, several treatment de-escalation trials have been conducted, but only a few of

281 g the design and implementation of future de-escalation trials.

282 evention trials and provide rationale for de-escalation trials.

283 omide) was initiated, and with subsequent re-escalation up to 25 mg lenalidomide, the MTD was not rea

284 ay cycle in a rolling 6 study design with de-escalation upon dose-limiting toxicities to establish th

285 s a difference in the frequency of unplanned escalations using different rapid response models, with

286 De-escalation varied among hospitals (median 37%, range 31-

287 Potential correlates of AAM escalation (vs no change) or de-escalation (vs no change

288 lates of AAM escalation (vs no change) or de-escalation (vs no change) were evaluated using multivari

289 Escalation was an increase in either number or rank.

290 cular analyses revealed that this resistance escalation was associated with a massive overexpression

291 Superiority for dose escalation was declared if the one-sided p value with Fi

292 De-escalation was defined as reduction in either the number

293 Treatment escalation was more common with increasing age and in ch

294 nically significant perforation), whereas de-escalation was more frequent among patients taking more

295 De-escalation was not associated with clinical failure or l

296 Dose escalation was not permitted in either group.

297 Dose escalation was performed from 104 to 107 TCID50 (50% tis

298 biotic de-escalation, and associations of de-escalation with outcomes.

299 biotic de-escalation, and associations of de-escalation with outcomes.

300 whom received combination therapy with dose escalation, with a median follow-up of 7.1 months (IQR 5